From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Tofacitinib | PBO | Tofacitinib | PBO | ||||
---|---|---|---|---|---|---|---|---|
Rate, % | +MTX N=52 | -MTX N=20 | +MTX N=54 | -MTX N=16 | Prior bDMARDs N=23 | No prior bDMARDs N=49 | Prior bDMARDs N=20 | No prior bDMARDs N=50 |
JIA flare | 28.9 | 30.0 | 48.2 | 68.8 | 26.1 | 30.6 | 70.0 | 46.0 |
JIA/ACR50a | 65.4 | 70.0 | 51.9 | 31.3 | 73.9 | 63.3 | 30.0 | 54.0 |
JIA/ACR70a | 53.9 | 55.0 | 40.7 | 25.0 | 47.8 | 57.1 | 25.0 | 42.0 |
JIA/ACR90a | 36.5 | 30.0 | 24.1 | 12.5 | 26.1 | 38.8 | 10.0 | 26.0 |
JIA/ACR-ID | 25.0 | 30.0 | 18.5 | 12.5 | 17.4 | 30.6 | 5.0 | 22.0 |
∆JADAS27-CRP, LSM (N) | 0.9 (36) | -2.4 (13) | 3.6 (27) | 2.3 (5) | -1.1 (16) | 0.8 (33) | 12.1 (6) | 4.4 (26) |